We hosted UCB’s roadshow in Paris last Friday with IR, Antje Witte and CMO, Iris Low-Friedrich. Concerns over romozozumab’s safety are groundless at the moment. Biosimilars in the US should not affect Cimzia or to a lesser extent considering 3rd line use, seven indications and an ongoing study vs. Humira. Future less clouded following epra failure but early-stage pipeline not expected to be in phase III before 2017 year end and bolt-on M&A with a more flexible financial situation towards the mid-year does not seems to be a priority.
For more information, please contact firstname.lastname@example.org